SG11201806140SA - Stable liquid gonadotropin formulation - Google Patents
Stable liquid gonadotropin formulationInfo
- Publication number
- SG11201806140SA SG11201806140SA SG11201806140SA SG11201806140SA SG11201806140SA SG 11201806140S A SG11201806140S A SG 11201806140SA SG 11201806140S A SG11201806140S A SG 11201806140SA SG 11201806140S A SG11201806140S A SG 11201806140SA SG 11201806140S A SG11201806140S A SG 11201806140SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- formulation
- english
- february
- Prior art date
Links
- 102000006771 Gonadotropins Human genes 0.000 title abstract 4
- 108010086677 Gonadotropins Proteins 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000002622 gonadotropin Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000007788 liquid Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940094892 gonadotropins Drugs 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603280.7A GB201603280D0 (en) | 2016-02-24 | 2016-02-24 | Stable liquid gonadotropin formulation |
| PCT/EP2017/054325 WO2017144659A1 (en) | 2016-02-24 | 2017-02-24 | Stable liquid gonadotropin formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806140SA true SG11201806140SA (en) | 2018-08-30 |
Family
ID=55806922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806140SA SG11201806140SA (en) | 2016-02-24 | 2017-02-24 | Stable liquid gonadotropin formulation |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10792334B2 (es) |
| EP (3) | EP4257149A3 (es) |
| JP (3) | JP6932710B2 (es) |
| KR (1) | KR20180114178A (es) |
| CN (2) | CN113398250B (es) |
| AR (1) | AR107782A1 (es) |
| AU (2) | AU2017222292B2 (es) |
| BR (1) | BR112018015166A2 (es) |
| CA (1) | CA3012759A1 (es) |
| CL (1) | CL2018001984A1 (es) |
| CO (1) | CO2018007810A2 (es) |
| DK (2) | DK3419595T3 (es) |
| EA (1) | EA036383B1 (es) |
| ES (2) | ES2966262T3 (es) |
| FI (1) | FI3791860T3 (es) |
| GB (1) | GB201603280D0 (es) |
| HR (2) | HRP20231477T1 (es) |
| HU (2) | HUE064432T2 (es) |
| IL (1) | IL260626B2 (es) |
| JO (1) | JOP20170046B1 (es) |
| LT (2) | LT3419595T (es) |
| MA (2) | MA43686B1 (es) |
| MD (2) | MD3419595T2 (es) |
| MX (1) | MX2018010201A (es) |
| MY (1) | MY193138A (es) |
| PH (1) | PH12018501688A1 (es) |
| PL (2) | PL3419595T3 (es) |
| PT (2) | PT3791860T (es) |
| RS (2) | RS64929B1 (es) |
| SG (1) | SG11201806140SA (es) |
| SI (2) | SI3791860T1 (es) |
| TN (1) | TN2018000284A1 (es) |
| TW (1) | TWI755377B (es) |
| UA (1) | UA123107C2 (es) |
| WO (1) | WO2017144659A1 (es) |
| ZA (1) | ZA201804944B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| WO2019164765A1 (en) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Ready-to-use dexmedetomidine compositions |
| WO2020071912A1 (en) * | 2018-10-02 | 2020-04-09 | Innocore Technologies B.V. | Extended release formulations of human chorionic gonadotropin (hcg) |
| CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| WO2022197963A1 (en) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Long-acting growth hormone compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0803832A3 (en) | 1996-02-28 | 2000-05-31 | Hitachi, Ltd. | Card holder-type balance display |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| WO2000004913A1 (en) * | 1998-07-23 | 2000-02-03 | Eli Lilly And Company | Fsh and fsh variant formulations, products and methods |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| EA019432B1 (ru) * | 2007-11-01 | 2014-03-31 | Мерк Сероно С.А. | Жидкие композиции lh |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| NZ586588A (en) | 2008-02-08 | 2012-10-26 | Biogenerix Ag | Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| RU2553375C2 (ru) | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
| WO2011108010A2 (en) | 2010-03-05 | 2011-09-09 | Intas Biopharmaceuticals Limited | A thermostable liquid formulation of gonadotropins |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| CN105658201A (zh) * | 2013-11-12 | 2016-06-08 | 卡迪拉保健有限公司 | 促性腺激素的制剂 |
| GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
-
2016
- 2016-02-24 GB GBGB1603280.7A patent/GB201603280D0/en not_active Ceased
-
2017
- 2017-02-19 JO JOP/2017/0046A patent/JOP20170046B1/ar active
- 2017-02-23 TW TW106106132A patent/TWI755377B/zh active
- 2017-02-24 ES ES20202758T patent/ES2966262T3/es active Active
- 2017-02-24 MA MA43686A patent/MA43686B1/fr unknown
- 2017-02-24 ES ES17707527T patent/ES2862193T3/es active Active
- 2017-02-24 MD MDE20190039T patent/MD3419595T2/ro unknown
- 2017-02-24 CN CN202110585922.3A patent/CN113398250B/zh active Active
- 2017-02-24 EP EP23194814.2A patent/EP4257149A3/en active Pending
- 2017-02-24 PL PL17707527T patent/PL3419595T3/pl unknown
- 2017-02-24 PT PT202027587T patent/PT3791860T/pt unknown
- 2017-02-24 SI SI201731448T patent/SI3791860T1/sl unknown
- 2017-02-24 AR ARP170100475A patent/AR107782A1/es unknown
- 2017-02-24 AU AU2017222292A patent/AU2017222292B2/en active Active
- 2017-02-24 SI SI201730666T patent/SI3419595T1/sl unknown
- 2017-02-24 MX MX2018010201A patent/MX2018010201A/es unknown
- 2017-02-24 SG SG11201806140SA patent/SG11201806140SA/en unknown
- 2017-02-24 MA MA52595A patent/MA52595B1/fr unknown
- 2017-02-24 JP JP2018544561A patent/JP6932710B2/ja active Active
- 2017-02-24 FI FIEP20202758.7T patent/FI3791860T3/fi active
- 2017-02-24 EA EA201891905A patent/EA036383B1/ru not_active IP Right Cessation
- 2017-02-24 WO PCT/EP2017/054325 patent/WO2017144659A1/en active Application Filing
- 2017-02-24 HU HUE20202758A patent/HUE064432T2/hu unknown
- 2017-02-24 TN TNP/2018/000284A patent/TN2018000284A1/en unknown
- 2017-02-24 LT LTEP17707527.2T patent/LT3419595T/lt unknown
- 2017-02-24 UA UAA201809497A patent/UA123107C2/uk unknown
- 2017-02-24 RS RS20231172A patent/RS64929B1/sr unknown
- 2017-02-24 DK DK17707527.2T patent/DK3419595T3/da active
- 2017-02-24 MY MYPI2018001301A patent/MY193138A/en unknown
- 2017-02-24 KR KR1020187027128A patent/KR20180114178A/ko unknown
- 2017-02-24 HR HRP20231477TT patent/HRP20231477T1/hr unknown
- 2017-02-24 EP EP17707527.2A patent/EP3419595B1/en active Active
- 2017-02-24 PL PL20202758.7T patent/PL3791860T3/pl unknown
- 2017-02-24 CN CN201780013134.9A patent/CN108883061B/zh active Active
- 2017-02-24 DK DK20202758.7T patent/DK3791860T3/da active
- 2017-02-24 EP EP20202758.7A patent/EP3791860B1/en active Active
- 2017-02-24 MD MDE20210250T patent/MD3791860T2/ro unknown
- 2017-02-24 HU HUE17707527A patent/HUE053492T2/hu unknown
- 2017-02-24 RS RS20210361A patent/RS61604B1/sr unknown
- 2017-02-24 LT LTEP20202758.7T patent/LT3791860T/lt unknown
- 2017-02-24 BR BR112018015166A patent/BR112018015166A2/pt active Search and Examination
- 2017-02-24 CA CA3012759A patent/CA3012759A1/en active Pending
- 2017-02-24 PT PT177075272T patent/PT3419595T/pt unknown
- 2017-02-24 US US16/079,428 patent/US10792334B2/en active Active
-
2018
- 2018-07-17 IL IL260626A patent/IL260626B2/en unknown
- 2018-07-23 ZA ZA2018/04944A patent/ZA201804944B/en unknown
- 2018-07-23 CL CL2018001984A patent/CL2018001984A1/es unknown
- 2018-07-27 CO CONC2018/0007810A patent/CO2018007810A2/es unknown
- 2018-08-08 PH PH12018501688A patent/PH12018501688A1/en unknown
-
2020
- 2020-09-14 US US17/020,279 patent/US11666635B2/en active Active
-
2021
- 2021-03-03 HR HRP20210367TT patent/HRP20210367T1/hr unknown
- 2021-08-18 JP JP2021133422A patent/JP2021191760A/ja active Pending
-
2022
- 2022-01-05 AU AU2022200027A patent/AU2022200027A1/en active Pending
-
2023
- 2023-04-21 US US18/138,000 patent/US20230372447A1/en active Pending
- 2023-09-15 JP JP2023150308A patent/JP2023164573A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201806140SA (en) | Stable liquid gonadotropin formulation | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |